Adult Summary flowchart for Asthma Switch and Step Down to ENHCCG preferred inhaler choices
|
|
- Bernadette Neal
- 6 years ago
- Views:
Transcription
1 ENHCCG Adult Asthma Switch and Step Down Algorithms - Approved by Hertfordshire Medicines Management Committee June 2016 Page 1 of 6 Adult Summary flowchart for Asthma Switch and Step Down to ENHCCG preferred inhaler choices MDI: Metered dose inhaler DPI: Dry powder inhaler ICS: Inhaled corticosteroid LABA: Long acting β 2 -agonist Patient is currently being prescribed a combination ICS/LABA inhaler that is not an ENHCCG preferred choice Assess if the patient is suitable to be considered for stepping DOWN treatment (see page 2) or if the patient can be switched to a corresponding strength of an ENHCCG preferred inhaler choice If current Inhaler is: Seretide Evohaler MDI [125/25 or 250/25 strengths] If current Inhaler is: Symbicort Turbohaler DPI [400/12 and 200/6 strengths] Sirdupla MDI [125/25 & 250/25 strengths] Generic equivalent that contains the same ICS and LABA ingredients and is therapeutically equivalent to corresponding strengths of Seretide Evohaler Flutiform MDI [50/5, 125/5 & 250/10 strengths] Contains the same ICS dose to corresponding strengths of Seretide Evohaler but contains a different LABA ingredient (formoterol) Fostair MDI (beclometasone /formoterol) [100/6 strength] Contains a different ICS (beclometasone) and LABA ingredient (formoterol) to Seretide Evohaler DuoResp Spiromax DPI [320/9 and 160/4.5 strengths] Generic equivalent that contains the same ICS and LABA ingredients and is therapeutically equivalent to corresponding strengths of Symbicort Turbohaler DPI algorithm on page 3 algorithm on page 4 algorithm on page 5 algorithm on page 6 DuoResp Spiromax 320/9 provides a delivered dose of budesonide 320mcg and formoterol 9mcg. This is therapeutically equivalent to Symbicort Turbohaler 400/12 metered dose of budesonide 400mcg and formoterol 12mcg which also provides a delivered dose of budesonide 320mcg and formoterol 9mcg. DuoResp Spiromax 160/4.5 provides a delivered dose of budesonide 160mcg and formoterol 4.5mcg. This is therapeutically equivalent to Symbicort Turbohaler 200/6 metered dose of budesonide 200mcg and formoterol 6mcg which also provides a delivered dose of budesonide 160mcg and formoterol 4.5mcg.
2 ENHCCG Adult Asthma Switch and Step Down Algorithms - Approved by Hertfordshire Medicines Management Committee June 2016 Page 2 of 6 How to step adult patients down algorithm Does the patient have an up to date asthma action plan? Has inhaler use (patient reported and Rx history), inhaler technique, smoking status, adherence, trigger factors, medication side-effects and use of rescue medication been checked? Check expected use of inhaler against patient reported use. Has asthma been completely controlled for at least 3 months? LEVELS OF ASTHMA CONTROL - Assessment of current clinical control (preferably) over 4 weeks Characteristic Completely Controlled Partly Controlled Uncontrolled Daytime symptoms None (twice or less/week) >Twice/week Three or more RCP 3 Limitation on activities None Any features of Questions Nocturnal symptoms/awakening None Any partly Need for reliever/rescue treatment None (twice or less/week) >Twice/week controlled Lung Function (PEF or FEV 1 ) Normal <80% predicted or personal best (if known) asthma YES Does the patient have any exclusion criteria? Patient does not agree to step down Excacerbation, oral steroid course, GP/hospital visit due to worsening asthma in past 6 months Under respiratory specialist review or pregnant (only step down if agreed with specialist) Significant adverse outcomes from previous step down attempts. Consider 25% dose reduction if previously unable to step down by 50% Seasonal exacerbations. Reschedule step down review after season has ended Lifestyle considerations where stability crucial e.g. impending exam Maintenance and Reliever Therapy (MART) regime NO YES STEP the patient DOWN refer to ENHCCG Adult Asthma Guidelines and Step DOWN/Switch Algorithms: - 1. Consider reducing add on therapies before reducing ICS 2. Identify the combination inhaler and dose the patient is currently being prescribed. Identify which step (3-5) this product and dose represents 3. Refer to the relevant Step DOWN/Switch algorithm for the ICS product 4. Consider switching to an equivalent strength ENHCCG approved lower cost product for 1 month (to identify any issues/confirm stability) before stepping down. Ensure the patient is trained and can demonstrate they can use any potential new device. If issues with the new product identified return to original product before consideration for stepping down. 5. Reduce dose by 25% - 50%. The dose decrease is an individual clinical decision based on history of stability with respect to day to day symptoms, frequency of exacerbations and previous step down attempts. Consideration should be given to the current ICS dose and the inhaler product and strength that the patient is using. Keep the LABA dose the same when ICS dose when possible 6. Dose reductions of less than 50% may be complicated and may involve using combinations of separate inhalers. Further advice may be sought from respiratory specialist. Note: for patients at step 4 and 5: if also taking add-on therapies (e.g.montelukast, oral steroids), consider reducing/stopping these before attempting to reduce ICS dose. Seek further advice from specialist services. Check & reinforce inhaler technique + /- spacer Advise patient of importance of adherence Ensure patient has current asthma action plan Ensure patient understands if symptoms worsen when to increase dose and seek medical advice Agree a review date for 3 months time Patient review at 3 months Has the patient achieved complete asthma control in the last 3 months? (see Table 1) YES STEP the patient DOWN and repeat cycle If unclear, advise patient to complete peak flow diary and then re-assess NO NO DO NOT step patient down Consider reason for poor control or exclusion criteria. Action as appropriate. Consider STEP UP therapy for uncontrolled symptoms Considerations for Clinician Patients achieve complete asthma control at different rates. Discuss with the patient to decide whether to trial the current therapy for longer or to step upagain. Suggested discussion points with patient: 1. Any factor affecting adherence e.g. polypharmacy, social reasons or beliefs? 2. Any issues affecting ability to use inhaler e.g. dexterity? 3. Trigger factors e.g. smoking, pets, pollen, stress? 4. How long did it take the patient to achieve complete control last time? 5. What would be the potential consequences of an exacerbation and does the patient know what to do if this occurs? 6. What would the patient prefer to do? 7. Ensure patient has up to date selfmanagement/action plan. ACTION Clinicians should use their professional judgement to decide whether to continue trialling current therapy or to step up again. If continuing on current therapy, advise patient to monitor symptoms and reliever use and review again in one month. Advise patient to follow self-management plan if symptoms become problematic within this time. Refer to specialist service as necessary
3 ENHCCG Adult Asthma Switch and Step Down Algorithms - Approved by Hertfordshire Medicines Management Committee June 2016 Page 3 of 6 Asthma Step DOWN/Switch Algorithm for Seretide Evohaler and Sirdupla in Adults (>18yrs) (devised from BTS/SIGN guidance and the relevant Summary of Product Characteristics) Ensure patient has achieved complete asthma control before stepping down (see Page 2) Sirdupla MDI is a therapeutically equivalent alternative to Seretide Evohaler. It is an ENHCCG approved lower cost ICS/LABA fixed dose combination MDI for asthma. It is lower cost for patients on Seretide Evohaler (prescribed by brand or generic) to be switched to the equivalent corresponding strength Sirdupla MDI. PRESCRIBE BY BRAND NAME - Up to 2000mcg BDP* equivalent/day - Addition of 4 th drug (e.g. montekukast, SR theophylline) } Consider reducing these - Addition of 5 th drug oral prednisolone [Step 5] } before reducing the ICS - Up to 800mccg BDP* equivalent/day Seretide 250 Evohaler [MDI] 2 puffs bd ( 59.48) (2000mcg BDP* equiv/day Sirdupla 250 [MDI] 2 puffs bd ( 44.61) (2000mcg BDP* equiv./day Seretide 125 Evohaler [MDI] 2 puffs bd ( 35.00) (1000mcg BDP* equiv/day Sirdupla 125 [MDI] 2 puffs bd ( 26.25) (1000mcg BDP* equiv./day Step down to lower strength Sirdupla /Flutiform MDI Seretide 50 Evohaler [MDI] 2 puffs bd ( 18.00) (400mcg BDP* equiv/day Flutiform 50 [MDI] 2 puffs bd ( 14.40) (400mcg BDP* equiv./day + 20mcg formoterol/day) Clenil Modulite [MDI] 100mcg (beclometasone) 2 puffs bd ( 4.45) Qvar [MDI] 50mcg (fine particle beclometasone) 2 puffs bd ( 4.72) [NB Qvar twice as potent as Clenil ) Flixotide 50 Evohaler [MDI] (fluticasone) 2 puffs bd ( 5.44) (if the patient cannot tolerate a change in ICS from fluticasone) Switch to equivalent strength Sirdupla / Flutiform MDI (review after 1 month to identify any issues before consideration for step down. Switch back to Seretide if issues identified) Step down to lower strength Seretide Evohaler (if cannot use Sirdupla eg cannot have alcohol or Flutiform eg cannot have alcohol/formoterol or issues when switched to Sirdupla) If patient is at, consider respiratory specialist advice on how to manage step down process, particularly if a more gradual ICS dose reduction (<50%) is required than the combination devices in the above algorithm allow. This may involve using combinations of different inhalers. If under respiratory specialist review - do not attempt step down without agreement of specialist. Key: There is not an equivalent strength Sirdupla inhaler for Seretide 50 Evohaler. Consider using Flutiform 50 MDI which contains the equivalent fluticasone dose as Seretide 50 Evohaler but a different LABA (formoterol) *Total daily dose inhaled corticosteroid (ICS), in terms of beclometasone dipropionate (BDP) equivalent Costs: 30 day costs (without a spacer) [Sep 2016] All patients with asthma should have an up to date asthma action plan and be provided with a short-acting beta 2 agonist (salbutamol MDI or Easyhaler ) to aid in the event of an exacerbation.
4 ENHCCG Adult Asthma Switch and Step Down Algorithms - Approved by Hertfordshire Medicines Management Committee June 2016 Page 4 of 6 Asthma Step DOWN/Switch Algorithm for Seretide Evohaler and Flutiform in Adults (>18yrs) (devised from BTS/SIGN guidance and the relevant Summary of Product Characteristics) Ensure patient has achieved complete asthma control before stepping down (see Page 2) Flutiform (fluticasone propionate/formoterol) is an ENHCCG approved lower cost ICS/LABA fixed dose combination MDI for asthma. It contains the equivalent dose of fluticasone to Seretide Evohaler but contains a different LABA (formoterol). It is lower cost for patients on Seretide Evohaler (prescribed by brand or generic) to be switched to equivalent strength Flutiform MDI. PRESCRIBE BY BRAND NAME - Up to 2000mcg BDP* equivalent/day - Addition of 4 th drug (e.g. montekukast, SR theophylline) } - Addition of 5 th drug oral prednisolone [Step 5] } - Up to 800mccg BDP* equivalent/day Seretide 250 Evohaler [MDI] 2 puffs bd ( 59.48) (2000mcg BDP* equiv/day Flutiform 250/10 [MDI] (fluticasone/fomoterol) 2 puffs bd ( 45.56) (2000mcg BDP* equiv./day + 40mcg formoterol/day) Seretide 125 Evohaler [MDI] 2 puffs bd ( 35.00) (1000mcg BDP* equiv/day Flutiform 125/5 [MDI] 2 puffs bd ( 28.00) (1000mcg BDP* equiv./day + 20mcg formoterol/day) Seretide 50 Evohaler [MDI] 2 puffs bd ( 18.00) (400mcg BDP* equiv/day Flutiform 50/5 [MDI] 2 puffs bd ( 14.40) (400mcg BDP* equiv./day + 20mcg formoterol/day) Clenil Modulite [MDI] 100mcg (beclometasone) 2 puffs bd ( 4.45) Qvar [MDI] 50mcg (fine particle beclometasone) 2 puffs bd ( 4.72) [NB Qvar twice as potent as Clenil ) Flixotide 50 Evohaler [MDI] (fluticasone) 2 puffs bd ( 5.44) (if the patient cannot tolerate a change in ICS from fluticasone) Step down to lower strength Flutiform MDI Switch to equivalent strength Flutiform MDI (review after 1 month to identify any issues before consideration for step down. Switch back to Seretide if issues identified) Step down to lower strength Seretide Evohaler (if cannot use Flutiform eg cannot have alcohol or intolerant to formoterol or issues when switched to Flutiform) If patient is at, consider respiratory specialist advice on how to manage step down process, particularly if a more gradual ICS dose reduction (<50%) is required than the combination devices in the above algorithm allow. This may involve using combinations of different inhalers. If under respiratory specialist review - do not attempt step down without agreement of specialist. Key: If taking add-on therapies e.g. montelukast, oral prednisolone, consider reducing these before reducing the ICS. * Total daily dose inhaled corticosteroid (ICS), in terms of beclometasone dipropionate (BDP) equivalent Costs: 30 day costs (without a spacer) [Sep 2016] All patients with asthma should have an up to date asthma action plan and be provided with a short-acting beta 2 agonist (salbutamol MDI or Easyhaler ) to aid in the event of an exacerbation.
5 ENHCCG Adult Asthma Switch and Step Down Algorithms - Approved by Hertfordshire Medicines Management Committee June 2016 Page 5 of 6 Asthma Step DOWN/Switch Algorithm for Seretide Evohaler and Fostair in Adults (>18yrs) (devised from BTS/SIGN guidance and the relevant Summary of Product Characteristics) Ensure patient has achieved complete asthma control before stepping down (see Page 2) Fostair (beclometasone/formoterol) is an ENHCCG approved lower cost ICS/LABA fixed dose combination MDI for asthma and COPD. It contains a different IC and LABA to that contained in Seretide. It is lower cost for patients on Seretide Evohaler (prescribed by brand or generic) to be switched to equivalent strength Fostair MDI. PRESCRIBE BY BRAND NAME - Up to 2000mcg BDP* equivalent/day - Addition of 4 th drug (e.g. montekukast, SR theophylline) - Addition of 5 th drug oral prednisolone [Step 5] - Up to 800mccg BDP* equivalent/day Seretide 250 Evohaler 2 puffs bd ( 59.48) (2000mcg BDP* equiv/day Seretide 125 Evohaler 2 puffs bd ( 35.00) (1000mcg BDP* equiv/day Fostair 100/6 MDI (beclometasone/formoterol) [1 puff = 250mcg BDP equiv. + 6 mcg formoterol] 2 puffs bd ( 29.32) (1000mcg BDP* equiv./day + 24mcg formoterol/day) Seretide 50 Evohaler 2 puffs bd ( 18.00) (400mcg BDP* equiv/day Fostair 100/6 MDI (beclometasone/formoterol) [1 puff = 250mcg BDP equiv. + 6 mcg formoterol] 1 puff bd ( 14.66) (500mcg BDP* equiv./day + 12mcg formoterol/day) Clenil Modulite [MDI] 100mcg (beclometasone) 2 puffs bd ( 4.45) Qvar [MDI] 50mcg (fine particle beclometasone) 2 puffs bd ( 4.72) [NB Qvar twice as potent as Clenil ) Flixotide 50 Evohaler [MDI] (fluticasone) 2 puffs bd ( 5.44) (if the patient cannot tolerate a change in ICS from fluticasone) Step down to lower BDP equiv. strength Fostair MDI Switch to equiv. BDP strength Fostair MDI (review after 1 month to identify any issues before consideration for step down. Switch back to Seretide if issues identified) Step down to lower strength Seretide Evohaler (if cannot use Fostair eg cannot have alcohol / beclometasone / formoterol or issues when switched to Fostair) If patient is at, consider respiratory specialist advice on how to manage step down process, particularly if a more gradual ICS dose reduction (<50%) is required than the combination devices in the above algorithm allow. This may involve using combinations of different inhalers. If under respiratory specialist review - do not attempt step down without agreement of specialist. Key: If taking add-on therapies e.g. montelukast, oral prednisolone, consider reducing these before reducing the ICS. * Total daily dose inhaled corticosteroid (ICS), in terms of beclometasone dipropionate (BDP) equivalent Costs: 30 day costs (without a spacer) [Sep 2016] All patients with asthma should have an up to date asthma action plan and be provided with a short-acting beta 2 agonist (salbutamol MDI or Easyhaler ) to aid in the event of an exacerbation.
6 ENHCCG Adult Asthma Switch and Step Down Algorithms - Approved by Hertfordshire Medicines Management Committee June 2016 Page 6 of 6 Asthma Step Down/Switch Algorithm for Symbicort quivalent/day Turbohaler and DuoResp Spiromax in Adults (>18yrs) (devised from BTS guidance and the relevant Summary of Product Characteristics) Ensure patient has achieved complete asthma control before stepping down (see page 2) DuoResp Spiromax is an ENHCCG approved lower cost ICS/LABA fixed dose combination dry powder inhaler (DPI) for asthma and COPD. It is therapeutically equivalent to corresponding strengths of Symbicort Turbohaler. It is lower cost for patients on Symbicort Turbohaler (prescribed by brand or generic) to be switched to the equivalent strength DuoResp Spiromax DPI. PRESCRIBE BY BRAND NAME - DuoResp Up to 2000mcg Spiromax BDP* equivalent/day - Addition of 4 th drug (e.g. montekukast, SR theophylline) - Addition of 5 th drug oral prednisolone [Step 5] - Up to 800mcg BDP* equivalent/day Symbicort Turbohaler 400/12 [1 puff = 400mcg BDP equiv.] 2 puffs bd ( 76.00) (1600mcg BDP* equiv./day + 48mcg formoterol/day) DuoResp Spiromax 320/9 [1 puff = 400mcg BDP equiv. 2 puffs bd ( 59.94) (1600mcg BDP* equiv./day + 48mcg formoterol/day) Symbicort Turbohaler 400/12 [1 puff = 400mcg BDP equiv.] 1 puff bd ( 38.00) Symbicort Turbohaler 200/6 [1 puff = 200mcg BDP equiv.] 2 puffs bd ( 38.00) (800mcg BDP* equiv./day + 24mcg formoterol/day) DuoResp Spiromax 320/9 [1 puff = 400mcg BDP equiv.] 1 puff bd ( 29.97) DuoResp Spiromax 160/4.5 [1 puff = 200mcg BDP equiv.] 2 puffs bd ( 29.97) (800mcg BDP* equiv/day + 24mcg formoterol/day) If patient is at, consider respiratory specialist advice on how to manage step down process, particularly if a more gradual ICS dose reduction (<50%) is required than the combination devices in the above algorithm allow. This may involve using combinations of different inhalers. If under respiratory specialist review - do not attempt step down without agreement of specialist. Symbicort Turbohaler 100/6 2 puffs bd ( 33.00) (400mcg BDP* equiv/day + 24mcg formoterol/day) Symbicort Turbohaler 200/6 [1 puff = 200mcg BDP equiv.] 1 puff bd ( 19.00) (400mcg BDP* equiv./day + 12mcg formoterol/day) DuoResp Spiromax 160/4.5 [1 puff = 200mcg BDP equiv] 1 puff bd ( 14.99) (400mcg BDP* equiv./day + 12mcg formoterol/day) Easyhaler Beclometasone 200mcg [DPI] 1 puff bd ( 4.48) Easyhaler Budesonide 200mcg [DPI] 1 puff bd ( 5.31) All patients with asthma should have an up to date asthma action plan and a short-acting beta 2 agonist (salbutamol MDI or Easyhaler ) to aid in the event of an exacerbation. Key: If taking add-on therapies e.g.oral prednisolone, montelukast, consider reducing these before reducing the ICS. * Total daily dose inhaled corticosteroid (ICS), in terms of beclometasone dipropionate (BDP) equivalent Costs: 30 days without a spacer [Sep2016] Step down to lower strength DuoResp Spiromax Switch to equivalent strength DuoResp Spiromax (review after 1 month to identify any issues before consideration for step down. Switch back to Symbicort if issues identified) Step down to lower strength Symbicort Turbohaler (if cannot use DuoResp eg issues with new device when switched to DuoResp)
Adult Summary flowchart for Asthma Switch and Step Down to preferred inhaler choices
HVCCG Adult Asthma Switch and Step Down Algorithms - Approved by Hertfordshire Medicines Management Committee June 2016 Page 1 of 6 Adult Summary flowchart for Asthma Switch and Step Down to preferred
More informationStepping-down combination ICS/LABA asthma inhaler therapy: Adults 18yrs
Step Down guidance Stepping-down combination ICS/LABA asthma inhaler therapy: Adults 18yrs Important Complete asthma control needs to be achieved for at least 12 weeks before attempting to step patients
More informationASTHMA TREATMENT GUIDE (ADULTS)
ASTHMA TREATMENT GUIDE (ADULTS) The BTS/SIGN guideline provides a wide range of information and guidance on the treatment of patients with asthma. https://www.brit-thoracic.org.uk/document-library/clinical-information/asthma/btssign-asthma-guideline-2016/
More informationInclude patients: with a confirmed diagnosis of asthma who have been free of asthma symptoms for 3 months or more.
Corby Clinical Commissioning Group Kettering General Hospital NHS Trust Nene Clinical Commissioning Group rthampton General Hospital NHS Trust rthamptonshire Healthcare Foundation Trust Stepping down asthma
More informationCHARM ASTHMA TREATMENT GUIDELINE
NHS City and Hackney Prescribing Guidelines Adults ( 12 years of age) CHARM ASTHMA TREATMENT GUIDELINE Written by: Hetal Dhruve (Specialist Respiratory Pharmacist, City and Hackney CCG) Checked by: Prof
More informationStepping down asthma treatment guidelines
Stepping down asthma treatment guidelines The potential for inhaled corticosteroids (ICS) to cause dose-related side-effects has led to asthma management guidelines recommending a dose reduction once asthma
More informationPosition within the Organisation
ASTHMA TREATMENT GUIDELINES Document Description Document Type Service Application Guidelines All healthcare professionals(hcps) caring for patients with asthma Version 4.0 Ratification date September
More informationGreater Manchester Asthma Management Plan 2018 Inhaler therapy options for adult patients (18 and over) with asthma
Greater Manchester Asthma Management Plan 2018 Inhaler therapy options for adult patients (18 and over) with asthma Non-pharmacological options for ALL patients, consider at ALL stages Make sure diagnosis
More informationAsthma Treatment Guideline for Adults (aged 17 and over)
Asthma Treatment Guideline for Adults (aged 17 and over) Sharon Andrew MLCSU January 2019 (Review date 0 January 2022) VERSION CONTROL. Please access via the LMMG website to ensure that the correct version
More informationBEDFORDSHIRE AND LUTON JOINT PRESCRIBING COMMITTEE
BEDFORDSHIRE AND LUTON JOINT PRESCRIBING COMMITTEE December 2014 Review Date: December 2017 Bulletin 206 : DuoResp Spiromax 160 / 4.5 and 320 / 9 budesonide & formoterol dry powder inhaler JPC Recommendations
More informationASTHMA PRESCRIBING GUIDELINES FOR ADULTS AND CHILDREN OVER 12
North Hampshire CCG Asthma Prescribing Guidelines June 2015 ASTHMA PRESCRIBING GUIDELINES FOR ADULTS AND CHILDREN OVER 12 These guidelines are based on the British Thoracic Society (BTS) and Scottish Intercollegiate
More informationGuide to Inhaled Treatment Choices
Guide to Inhaled Treatment Choices Note: this is guidance only, it is important to consider which device is best suited to the patient. This may NOT be the first line choice (but should be on the joint
More informationRespiratory Inhalers. Identification Guide Version 3
Respiratory Inhalers Identification Guide Version 3 This booklet has been prepared by NHSGGC Medicines Information. Endorsed by NHSGGC Respiratory Managed Clinical Network, February 2017. Designed by Medical
More informationGuide to Inhaled Treatment Choices
Guide to Inhaled Treatment Choices Note: this is guidance only, it is important to consider which device is best suited to the patient. This may NOT be the first line choice (but should be on the joint
More informationMedicines Optimisation Team Standard Operating Procedure for Audit: High Dose Inhaled Corticosteroids
Cannock Chase Clinical Commissioning Group South East Staffordshire and Seisdon Peninsula Clinical Commissioning Group Stafford and Surrounds Clinical Commissioning Group East Staffordshire Clinical Commissioning
More informationMedicines Management of Asthma
Wandsworth Borough Team Medicines Management of Guidelines for Primary Care September 2011 Version 1 Guideline Authors: Shaneez Dhanji (Wandsworth borough) Reena Rabheru-Dodhy (Sutton & Merton borough)
More informationPrescribing guidelines: Management of COPD in Primary Care
Prescribing guidelines: Management of COPD in Primary Care Establish diagnosis of COPD in patients 35 years with appropriate symptoms with history, examination and spirometry (FEV1/FVC ratio < 70%) Establish
More informationbeclometasone 100 MDI 2 puffs twice a day (recently changed to non CFC (Clenil Modulite))
Case 1 Mr Thomson, a 32 year old asthmatic who is well known to you comes into your pharmacy. He is known to have a best peak flow of 640 L/min. He tells you that over the last few weeks he has been wakening
More informationGMMMG Asthma Formulary Inhaler Options August 2017
Regular Preventer Beclometasone Beclometasone Beclometasone Brand name Qvar Easi-Breathe Clenil Modulite Easyhaler Device MDI MDI DPI Strengths 50 microgram 100 microgram 200 microgram Adult asthma 2 inhalations
More information3. Respiratory System
1 3. Respiratory System Also see Appendix 3A Guidance on Management of Also see Appendix 3B Preferred Inhaler Devices for Adults Also see Appendix 3C Preferred Inhaler Devices for Adolescents (12-18 years)
More informationAPPENDIX 1 Printable point-of-care tables Asthma Action Plan Yellow Zone Formulation Table Region: Europe
APPENDIX 1 Printable point-of-care tables Asthma Action Plan Yellow Zone Formulation Table Region: Europe Instructions: Print on 8.5 x14 (216 x 279 mm) paper (Legal size) Medication in Green Zone Change
More informationDiagnosis and management of Asthma in Adults. (Version 1.1)
Pan-Birmingham Respiratory Clinical Network Diagnosis and management of Asthma in Adults (Version 1.1) Revision History Guideline Author: Guideline Sponsor: Date of Approval: 23/03/2017 Approved by: Date
More informationAllwin Mercer Dr Andrew Zurek
Allwin Mercer Dr Andrew Zurek 1 in 11 people are currently receiving treatment for asthma (5.4 million people in the UK) Every 10 seconds, someone is having a potentially life-threatening asthma attack
More informationAlgorithm for the use of inhaled therapies in COPD Version 2 May 2017
Algorithm for the use of inhaled therapies in COPD This document has been revised by the Berkshire West Respiratory Network to support clinicians in selecting the most appropriate, cost effective treatments
More informationSeretide 250mcg/125mcg Evohaler switch to Fostair 100/6 MDI in COPD.
Seretide 250mcg/125mcg Evohaler switch to Fostair 100/6 MDI in COPD. Applies to HaRD CCG employed Pharmacists and Medicines Optimisation Technicians These protocols are produced by the NY&AWC MM team hosted
More informationSABA: VENTOLIN EVOHALER (SALBUTAMOL) SAMA: ATROVENT IPRATROPIUM. Offer LAMA (discontinue SAMA) OR LABA
COPD GUIDELINES DIAGNOSIS >35 years of age Symptoms of cough, breathlessness, sputum, wheeze, Risk factor (SMOKING) Spirometry (post bronchodilator) FEV1/FVC = 0.7 ENCOURAGE PATIENTS TO BRING INHALERS
More informationAsthma Guidelines and Pharmacological Treatment. Dr James Wilkinson
Asthma Guidelines and Pharmacological Treatment Dr James Wilkinson Asthma is a common disease in the UK 5.4 million people in the UK are currently receiving treatment for asthma: 4.3 million adults (1
More informationInhaled Corticosteroids for the Treatment of Chronic Asthma in Adults & Adolescents aged 12 years & over
Manufacturer Submission To The National Institute for Health and Clinical Excellence By GlaxoSmithKline UK Inhaled Corticosteroids for the Treatment of Chronic Asthma in Adults & Adolescents aged 12 years
More informationGINA. At-A-Glance Asthma Management Reference. for adults, adolescents and children 6 11 years. Updated 2017
GINA At-A-Glance Asthma Management Reference for adults, adolescents and children 6 11 years Updated 2017 This resource should be used in conjunction with the Global Strategy for Asthma Management and
More informationCHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) TREATMENT GUIDELINES
CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) TREATMENT GUIDELINES Document Description Document Type Service Application Version Guidelines All healthcare professionals(hcps) caring for patients with asthma
More informationThe clinical effectiveness and costeffectiveness. treatment of chronic asthma in children under the age of 12 years
The clinical effectiveness and costeffectiveness of corticosteroids for the treatment of chronic asthma in children under the age of 12 years Submission of evidence from AstraZeneca UK Ltd regarding the
More informationDose. Route. Units. Given. Dose. Route. Units. Given
Chapter 4 Respiratory Andrew Stanton SALBUTAMOL (in acute asthma) 5 in acute asthma Nebulised (driven by oxygen not air) 4 6 hourly In acute severe asthma not responding to initial treatment or in life-threatening
More informationProgress, Paediatrics and Protocols. Dr Andy Powell Dr Lesley Ayling West Hampshire CCG
Progress, Paediatrics and Protocols Dr Andy Powell Dr Lesley Ayling West Hampshire CCG Progress Solutions CQUIN discharge bundle (including personal action plan), specialist review, immediate management
More informationAlgorithm for the use of inhaled therapies in COPD
Berkshire West Integrated Care System Representing Berkshire West Clinical Commisioning Group Royal Berkshire NHS Foundation Trust Berkshire Healthcare NHS Foundation Trust Berkshire West Primary Care
More informationMedicines Management of Chronic Obstructive Pulmonary Disease (COPD)
Medicines Management of Chronic Obstructive Pulmonary Disease (COPD) (Chronic & Acute) Guidelines for Primary Care Guideline Authors: Shaneez Dhanji (Wandsworth CCG) Samantha Prigmore (St George s Hospital)
More informationChapter 3: Respiratory System (7 th Edition)
Chapter 3: Respiratory System (7 th Edition) The Sheffield respiratory guidelines (April 2015) have been removed from the intranet. This is because the COPD section has been superseded by the COPD treatment
More informationNHS Dumfries & Galloway Triple therapy in COPD patients over 16 years
Title of Project: NHS Dumfries & Galloway Triple therapy in COPD patients over 16 years 1 Reason for the review Respiratory prescribing is long term and can be costly. Appropriate choice and use of inhaled
More informationTHEOPHYLLINE WITH INHALED CORTICOSTEROIDS (TWICS) TRIAL SELF MANAGMENT / ACTION PLANS GENUAIR INHALERS: POTENTIAL SAFETY ISSUE
I S S U E 4 M A R C H / A R P I L 2 0 1 6 Endorsed December 2014 I N S I D E T H I S I S S U E : Theophylline with Inhaled Corticosteroids (TWICS) Trial Genuair Inhaler: Potential Safety Issue 1 Self Management
More informationSummary of Lothian Joint Formulary Amendments
Summary of Lothian Joint Formulary Amendments The purpose of this summary is to detail the main changes to the LJF sections and provide additional information on the reasons for some of the changes. The
More informationTips on managing asthma in children
Tips on managing asthma in children Dr Ranjan Suri Consultant in Respiratory Paediatrics Bupa Cromwell Hospital Clinics: Friday (pm) Asthma in Children Making the diagnosis Patterns of childhood asthma
More informationGlobal Initiative for Asthma (GINA) What s new in GINA 2016?
Global Initiative for Asthma (GINA) What s new in GINA 2016? GINA Global Strategy for Asthma Management and Prevention GINA: A Brief History Established in 1993 Collaboration between NHLBI and WHO Multiple
More informationfluticasone furoate / vilanterol 92/22, 184/22 micrograms inhalation powder (Relvar Ellipta ) SMC No. (966/14) GlaxoSmithKline UK
fluticasone furoate / vilanterol 92/22, 184/22 micrograms inhalation powder (Relvar Ellipta ) SMC No. (966/14) GlaxoSmithKline UK 09 May 2014 The Scottish Medicines Consortium (SMC) has completed its assessment
More informationWhy Asthma Still Kills The National Review of Asthma Deaths (NRAD)
APPROVED FINAL VERSION NHS Protect Why Asthma Still Kills The National Review of Asthma Deaths (NRAD) Summary of Recommendations for GP Practices and Community Pharmacies Author: Anne Henry Contact: anne.henry@nhs.net
More informationASTRAZENECA v GLAXOSMITHKLINE
CASE AUTH/1986/4/07 ASTRAZENECA v GLAXOSMITHKLINE Symbicort and Seretide cost comparisons AstraZeneca complained about cost comparisons made by GlaxoSmithKline between AstraZeneca s Symbicort (budesonide/formoterol)
More informationWirral COPD Prescribing Guidelines
Wirral COPD Prescribing Guidelines (To be read in conjunction with the Wirral COPD Supplementary Information) STEP 1: Assess symptoms COPD Assessment Test (CAT) [Link for CAT-test Online] is a patient-completed
More informationAsthma training. Mike Levin Division of Asthma and Allergy Red Cross Hospital
Asthma training Mike Levin Division of Asthma and Allergy Red Cross Hospital Introduction Physiology Diagnosis Severity Treatment Control Stage 3 of guidelines Acute asthma Drug delivery Conclusion Overview
More informationBEDFORDSHIRE AND LUTON JOINT PRESCRIBING COMMITTEE (JPC)
BEDFORDSHIRE AND LUTON JOINT PRESCRIBING COMMITTEE (JPC) February 2013, Updated September 2013 Review date: September 2016 Bulletin 176 : Choice of Inhaled Corticosteroid / Long Acting Beta 2 Agonist (ICS/LABA)
More informationChronic Obstructive Pulmonary Disease (COPD) Treatment Guidelines
Chronic Obstructive Pulmonary Disease (COPD) Treatment Guidelines Where appropriate the following should be offered before commencing inhaled treatment: Offer treatment and support to stop smoking. Smoking
More informationAddress Comorbidities
Greater Manchester COPD Management Plan Non-pharmacological management for ALL patients Smoking Cessation Annual Flu Vaccination Pulmonary Rehabilitation Increase daily activity Inhaler Technique Measure
More informationNot available 100/6mcg 2 BD formoterol (Fostair MDI) 100/6mcg 33
COMMISSIONING POLICY RECOMMENDATION TREATMENT ADVISORY GROUP FLUTICASONE FUROATE/VILANTEROL COMBINATION INHALER - ASTHMA Policy agreed by Vale of York CCG (date) Drug, Treatment, Device name Fluticasone
More informationAsthma - An update BTS Asthma Guidelines 2016
Asthma - An update BTS Asthma Guidelines 2016 Dr Ian Clifton Overview Diagnosis Supported self-management Non-pharmacological management Drugs / inhaled therapy Difficult asthma services Case discussions
More informationRespiratory Health. Asthma and COPD
Respiratory Health Asthma and COPD Definition of asthma Working definition by AAH 2014: Chronic lung disease Can be controlled not cured Large variation in lung function Large variation in respiratory
More informationcontrol in the lowest dose providing adequate Maintain high dose ICS Use daily steroid tablet dose Consider trials of: Increasing ICS up to
Summary of management in adults sthma - suspected dult asthma - diagnosed Diagnosis and ssessment Evaluation: assess symptoms, measure lung function, check inhaler technique and adherence adjust dose update
More informationASTHMA. Dr Liz Gamble BRI
ASTHMA Dr Liz Gamble BRI Diagnosis Clinical: wheeze, breathlessness, chest tightness, cough Variable airflow obstruction: peak flow chart, spirometry with reversibility to bronchodilators Airways hyper-responsiveness
More informationIvax Pharmaceuticals UK Sponsor Submission to the National Institute for Health and Clinical Excellence
Ivax Pharmaceuticals UK Sponsor Submission to the National Institute for Health and Clinical Excellence Clinical and cost-effectiveness of QVAR for the treatment of chronic asthma in adults and children
More informationBNF CHAPTER 3: RESPIRATORY
3.1 BRONCHODILATORS BNF CHAPTER 3: RESPIRATORY 3.1.1.1 SELECTIVE BETA 2 -AGONISTS Short acting Salbutamol 100 micrograms/actuation aerosol inhaler 100 micrograms/actuation breath-actuated (e.g., Easi-Breathe
More informationAlberta Childhood Asthma Pathway for Primary Care
Asthma Diagnosis Box 1 Diagnosis: Based on symptom pattern, careful and thorough history of symptoms (wheeze, cough, night waking and activity limitations), and assessment of family history of asthma and
More informationAsthma Assessment & Review
ASTHMA RESOURCE PACK Section 5B Asthma Assessment & Review In this section: 1. Primary Care initial assessment and review Asthma Resource Pack Section 5B: Asthma Assessment & Review Version 3.0 Last Updated:
More informationCHARM Guidelines for the diagnosis and
\ CHARM Guidelines for the diagnosis and management of COPD City and Hackney CCG Homerton University Hospital NHS Foundation Trust Written by: Miss Hetal Dhruve, Specialist Pharmacist Respiratory Medicine,
More informationGetting Asthma treatment right. Dr David Cremonesini Specialist Pediatrician American Hospital
Getting Asthma treatment right Dr David Cremonesini Specialist Pediatrician American Hospital cdavid@ahdubai.com } Consultant Paediatrician from UK of 5.5 years } Speciality in Allergy / Asthma (PG Certificate)
More informationAWMSG SECRETARIAT ASSESSMENT REPORT
AWMSG SECRETARIAT ASSESSMENT REPORT Fluticasone furoate/vilanterol (as trifenatate) (Relvar Ellipta ) inhalation powder, 184/22 inhalation powder Reference number: 1216 FULL SUBMISSION This report has
More informationNHS Northern, Eastern and Western Devon Clinical Commissioning Group NHS South Devon and Torbay Clinical Commissioning Group
NHS Northern, Eastern and Western Devon Clinical Commissioning Group NHS South Devon and Torbay Clinical Commissioning Group Inhaler technique and respiratory conditions Guidance Sheet 16 When diagnosed
More informationChoosing an inhaler for COPD made simple. Dr Simon Hart Castle Hill Hospital
Choosing an inhaler for COPD made simple Dr Simon Hart Castle Hill Hospital 1 Declaration of interests I have received speaker fees, sponsorship to attend conferences, and funding for research from companies
More informationOnline supplementary material
Online supplementary material Add-on long-acting β2-agonist (LABA) in a separate inhaler as asthma step-up therapy versus increased dose of inhaled corticosteroid (ICS) or ICS/LABA combination inhaler
More informationOn completion of this chapter you should be able to: discuss the stepwise approach to the pharmacological management of asthma in children
7 Asthma Asthma is a common disease in children and its incidence has been increasing in recent years. Between 10-15% of children have been diagnosed with asthma. It is therefore a condition that pharmacists
More informationTechnology appraisal guidance Published: 28 November 2007 nice.org.uk/guidance/ta131
Inhaled corticosteroids for the treatment of chronic asthma in children under the age of 12 years Technology appraisal guidance Published: 28 November 2007 nice.org.uk/guidance/ta131 NICE 2018. All rights
More informationADULT ASTHMA GUIDE SUMMARY. This summary provides busy health professionals with key guidance for assessing and treating adult asthma.
ADULT ASTHMA GUIDE SUMMARY This summary provides busy health professionals with key guidance for assessing and treating adult asthma. Its source document Asthma and Respiratory Foundation NZ Adult Asthma
More informationInhaled corticosteroids for the treatment of chronic asthma in children under the age of 12 years. Issue date: November 2007
Issue date: November 2007 Review date: November 2012 Inhaled corticosteroids for the treatment of chronic asthma in children under the age of 12 years NICE technology appraisal guidance 131 NICE technology
More informationASTRAZENECA v GLAXOSMITHKLINE
CASE AUTH/1833/5/06 ASTRAZENECA v GLAXOSMITHKLINE CONCEPT study leavepiece AstraZeneca complained that a leavepiece issued by Allen & Hanburys, part of GlaxoSmithKline, did not present a fair and balanced
More informationTHE COPD PRESCRIBING TOOL
THE COPD PRESCRIBING TOOL Revised edition, 2017 www.bpac.org.nz/copd CLASSIFICATION The COPD prescribing tool This tool provides pharmacological treatment options for patients with COPD based on their
More informationCOPD Inhaled Therapy Prescribing Guidance
COPD Inhaled Therapy Prescribing Guidance For Basingstoke, Southampton and Winchester District Prescribing Committee This guidance applies to patients with a COPD DIAGNOSIS CONFIRMED BY POSTBRONCHODILATOR
More informationCo. Durham & Darlington Respiratory Network COPD Treatment Guide
Co. Durham & Darlington Respiratory Network COPD Treatment Guide Age > 35, Productive cough, Breathless, Smoking Hx Spirometry (post-bronchodilator) COPD Advice Intensive smoking cessation support Vaccination
More informationDR REBECCA THOMAS CONSULTANT RESPIRATORY PHYSICIAN YORK DISTRICT HOSPITAL
DR REBECCA THOMAS CONSULTANT RESPIRATORY PHYSICIAN YORK DISTRICT HOSPITAL Definition Guidelines contact complicated definitions Central to this is Presence of symptoms Variable airflow obstruction Diagnosis
More informationScottish Medicines Consortium
Scottish Medicines Consortium budesonide/formoterol 100/6, 200/6 turbohaler (Symbicort SMART ) No. (362/07) Astra Zeneca UK Limited 9 March 2007 (Issued May 2007) The Scottish Medicines Consortium (SMC)
More informationInformation for Parents and Young People on New and Emerging Treatments in Asthma
Information for Parents and Young People on New and Emerging Treatments in Asthma Asthma continues to be a very common condition that causes a lot of distress to children and their families. For some it
More informationAdjustment of Inhaled Controller Therapy of Asthma in the Yellow Zone, Based on the Inhaler Product Used in the Green Zone Age 16 Years and Older
Adjustment of Inhaled Controller Therapy of Asthma in the Yellow Zone, Based on the Inhaler Product Used in the Green Zone Age 16 Years and Older The Canadian Thoracic Society and other international asthma
More informationCOPD Inhaled Therapy Prescribing Guidance
COPD Inhaled Therapy Prescribing Guidance For Basingstoke, Southampton and Winchester District Prescribing Committee This guidance applies to patients with a COPD DIAGNOSIS CONFIRMED BY POSTBRONCHODILATOR
More informationMedicines Management Programme Inhaled Medicines for Chronic Obstructive Pulmonary Disease (COPD)
Medicines Management Programme Inhaled Medicines for Chronic Obstructive Pulmonary Disease (COPD) Approved by Prof. Michael Barry, Clinical Lead, MMP. Date approved Version 1 July 2014 Date updated Version
More informationAustralian Asthma Handbook. Key table and figures Version 1.2
Australian Asthma Handbook Key table and figures Version 1.2 DIAGNOSIS OF ASTHMA Figure. Steps in the diagnosis of asthma in adults Table. Findings that increase or decrease the probability of asthma in
More informationCOPD RESOURCE PACK Section 5. Drug Treatment & Inhalers in Stable COPD
COPD RESOURCE PACK Section 5 Drug Treatment & Inhalers in Stable COPD In this section: 1. Links to Fife Formulary 2. Pharmacological Management of Stable COPD 3. How to use a Metered Dose Inhaler 4. How
More informationGMMMG COPD Formulary Inhaler Options October 2017
BNF 3.1.1 Adrenocepter agonists (SABA) Salbutamol Salbutamol Terbutaline Brand name Airsalb Ventolin Evohaler Bricanyl Turbohaler Device MDI MDI Dry powder Strengths 100 microgram 100 microgram 500 microgram
More informationII: Moderate Worsening airflow limitations Dyspnea on exertion, cough, and sputum production; patient usually seeks medical
Table 3.1. Classification of COPD Severity Stage Pulmonary Function Test Findings Symptoms I: Mild Mild airflow limitations +/ Chronic cough and sputum production; patient unaware of abnormal FEV 1 80%
More informationAsthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing
Asthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing Diana M. Sobieraj, PharmD, BCPS Assistant Professor University of Connecticut School
More informationClinical Practice Guideline: Asthma
Clinical Practice Guideline: Asthma INTRODUCTION A critical aspect of the diagnosis and management of asthma is the precise and periodic measurement of lung function both before and after bronchodilator
More informationMANAGING ASTHMA. Nancy Davis, RRT, AE-C
MANAGING ASTHMA Nancy Davis, RRT, AE-C What is asthma? Asthma is a chronic respiratory disease characterized by episodes or attacks of inflammation and narrowing of small airways in response to asthma
More informationASTHMA & RESPIRATORY FOUNDATION NZ ADULT ASTHMA GUIDELINES: A QUICK REFERENCE GUIDE 1
ASTHMA & RESPIRATORY FOUNDATION NZ ADULT ASTHMA GUIDELINES: A QUICK REFERENCE GUIDE 1 1. Richard Beasley, Bob Hancox, Matire Harwood, Kyle Perrin, Betty Poot, Janine Pilcher, Jim Reid, Api Talemaitoga,
More informationImproving Outcomes in the Management & Treatment of Asthma. April 21, Spring Managed Care Forum
Improving Outcomes in the Management & Treatment of Asthma April 21, 2016 2016 Spring Managed Care Forum David M. Mannino, M.D. Professor Department of Preventive Medicine and Environmental Health University
More informationDifficult Asthma Assessment: A systematic approach
Difficult Asthma Assessment: A systematic approach Dr Naghmeh Radhakrishna Respiratory, Sleep & Allergy Physician Allergy, Asthma & Clinical Immunology Service The Alfred Hospital Melbourne, Australia
More informationDisclosure. Case. Objectives. Case Continued. Inhalers. Asthma: A GINA Update to the NAEPP 2007 Guidelines 1/20/2015
Disclosure Asthma: A GINA Update to the NAEPP 2007 Guidelines Robert (RC) Hellinga, Pharm.D. PGY 1 Pharmacy Resident Wolfson Children s Hospital/Baptist Health I do not have a vested interest in or affiliation
More information(PLACE PATIENT LABEL HERE) Date: Time: Assessment nurse: Sign: STOP!
ASTHMA BEST CARE BUNDLE P A T H W A Y ADULT ASTHMA Date: Time: Assessment nurse: Sign: INCLUSION CRITERIA Known asthmatic Shortness of breath and / or wheeze EXCLUSION CRITERIA Chronic lung disease other
More information500 micrograms/dose Turbohaler dry powder device 500 micrograms/ml injection. 12 micrograms/dose Turbohaler dry powder device
3.1 BRONCHODILATORS 3.1.1.1 SELECTIVE BETA 2 -AGONISTS Short acting Salbutamol Terbutaline 100 micrograms/actuation aerosol inhaler 100 micrograms/actuation breath-actuated e.g. Easi-Breathe 200 micrograms/dose
More informationPractical Approach to Managing Paediatric Asthma
Practical Approach to Managing Paediatric Asthma Dr Andrew Tai FRACP, PhD Paediatric Respiratory and Sleep Specialist Women's and Children's Hospital, Adelaide Approaching the patient Check the diagnosis
More informationPredicting, Preventing and Managing Asthma Exacerbations. Heather Zar Department of Paediatrics & Child Health University of Cape Town South Africa
Predicting, Preventing and Managing Asthma Exacerbations Heather Zar Department of Paediatrics & Child Health University of Cape Town South Africa Asthma exacerbations Predicting exacerbation recognising
More informationIf you require this document in another format such as Braille, large print, audio or another language please contact the Trusts Communications Team
MANAGEMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) IN ADULTS Summary statement: How does the document support patient care? Staff/stakeholders involved in development: Job titles only Division:
More informationDiagnosis, Assessment, Monitoring and Pharmacological Treatment of Asthma
Diagnosis, Assessment, Monitoring and Pharmacological Treatment of Asthma Magnitude of Asthma - India Delhi Childhood asthma: 10.9% Adults: 8% Other Cities 3 to 18% Chhabra SK et al Ann Allergy Asthma
More informationTreatment choices for patients with asthma or COPD. Jo Riley Lead Nurse For Oxfordshire Respiratory Service
Treatment choices for patients with asthma or COPD Jo Riley Lead Nurse For Oxfordshire Respiratory Service What is the difference? Is it all about? Inhaled steroids Long acting ß2 agonists Short acting
More informationAsthma Update A/Prof. John Abisheganaden. Senior Consultant, Dept Of Respiratory & Crit Care Medicine Tan Tock Seng Hospital
Asthma Update - 2013 A/Prof. John Abisheganaden Senior Consultant, Dept Of Respiratory & Crit Care Medicine Tan Tock Seng Hospital Asthma A complex syndrome Multifaceted disease Heterogeneous Genetic and
More informationAsthma: Chronic Management. Yung-Yang Liu, MD Attending physician, Chest Department Taipei Veterans General Hospital April 26, 2015
Asthma: Chronic Management Yung-Yang Liu, MD Attending physician, Chest Department Taipei Veterans General Hospital April 26, 2015 Global Strategy for Asthma Management and Prevention Evidence-based Implementation
More informationBeclometasone dipropionate (BDP) Prophylactic management of mild, moderate or severe asthma in adults
CLENIL MODULITE Beclometasone dipropionate (BDP) Prophylactic management of mild, moderate or severe asthma in adults Corticosteroids for the treatment of chronic asthma in adults and children aged 12
More information